NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc.

$0.45
-0.02 (-4.91%)
AMEX
USD, US
Biotechnology

NBY Price Chart

Basic
Market Cap$2.18M
Price$0.45
52 Week Range0.36-44.8
Beta0.726
Margins
Gross Profit Margin58.59%
Operating Profit Margin-37.78%
Net Profit Margin-88.77%
Valuation (TTM)
P/E Ratio-0.05
Price to Sales Ratio0.18
Price to Book Ratio-0.83
PEG Ratio-0.00

Industry

Biotechnology

Sector

Healthcare

CEO

Mr. Justin M. Hall Esq.

Full-Time Employees

24

IPO Date

2007-10-26

Description

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Phone

510 899 8800

Address

2000 Powell Street, EmeryVille, CA, 94608, US

CIK

0001389545